Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Enzo Biochem Schedules Teleconference to Discuss 2012 Third Quarter Results on June 12, 2012 at 8:30 AM E.T.



  Enzo Biochem Schedules Teleconference to Discuss 2012 Third Quarter Results
  on June 12, 2012 at 8:30 AM E.T.

Business Wire

NEW YORK -- June 06, 2012

Enzo Biochem, Inc. (NYSE: ENZ), will hold a conference call to discuss fiscal
2012 third quarter results on Tuesday, June 12, 2012, at 8:30 AM E.T.

To listen to the conference call dial 1-888-459-5609. International callers
can dial 1-973-321-1024. When prompted, use PIN number 87825581. Dial in
approximately ten minutes prior to the scheduled teleconference time. A
rebroadcast of the call will be available starting approximately two hours
after the conference call ends, through midnight (E.T.) Tuesday, June 26,
2012. The replay of the conference call can be accessed by dialing
1-800-585-8367 (International callers can dial 1-404-537-3406) and, when
prompted, use the same PIN number 87825581.

Enzo’s conference call can also be accessed live over the Internet at
http://phoenix.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=94391&eventID=4789250

To listen to the live call, individuals should go to the web site at least 15
minutes early to register, download and install any necessary audio software.
Any pop up blocker installed on your PC should be disabled while accessing the
webcast. A replay will be available for two weeks after the original
broadcast.

A press release announcing third quarter results will be distributed Monday,
June 11, 2012 after the market close.

Enzo Biochem is engaged in the research, development and manufacture of
innovative health care products based on molecular biology and genetic
engineering techniques, and in providing diagnostic services to the medical
community.

Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside
of the control of the company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other expenses,
government regulations, litigations, and general business conditions. See Risk
Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2010.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a result
of developments occurring after the date of this press release.

Contact:

For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232
or
CEOcast, Inc
Michael Wachs, 212-732-4300
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement